KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to -$15.9 million.

  • Emergent BioSolutions' Cash from Financing Activities rose 9118.14% to -$15.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$22.2 million, marking a year-over-year increase of 8805.17%. This contributed to the annual value of -$190.0 million for FY2024, which is 6453.24% up from last year.
  • Latest data reveals that Emergent BioSolutions reported Cash from Financing Activities of -$15.9 million as of Q3 2025, which was up 9118.14% from -$6.4 million recorded in Q2 2025.
  • In the past 5 years, Emergent BioSolutions' Cash from Financing Activities registered a high of $353.1 million during Q4 2022, and its lowest value of -$486.9 million during Q2 2023.
  • In the last 5 years, Emergent BioSolutions' Cash from Financing Activities had a median value of -$10.5 million in 2023 and averaged -$21.5 million.
  • In the last 5 years, Emergent BioSolutions' Cash from Financing Activities tumbled by 468260.87% in 2021 and then soared by 468600.0% in 2022.
  • Over the past 5 years, Emergent BioSolutions' Cash from Financing Activities (Quarter) stood at -$110.0 million in 2021, then surged by 421.0% to $353.1 million in 2022, then tumbled by 98.67% to $4.7 million in 2023, then tumbled by 89.36% to $500000.0 in 2024, then tumbled by 3280.0% to -$15.9 million in 2025.
  • Its last three reported values are -$15.9 million in Q3 2025, -$6.4 million for Q2 2025, and -$400000.0 during Q1 2025.